AR009543A1 - Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. - Google Patents
Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados.Info
- Publication number
- AR009543A1 AR009543A1 ARP970104059A ARP970104059A AR009543A1 AR 009543 A1 AR009543 A1 AR 009543A1 AR P970104059 A ARP970104059 A AR P970104059A AR P970104059 A ARP970104059 A AR P970104059A AR 009543 A1 AR009543 A1 AR 009543A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- hydroxy
- halogen
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen un fragmento derivado del ácido carbonico de formula (Ia) y derivados de ácido carbonico de la formula (I), en donde R1 es tetrazol o a ungrupo, R2 es hidrogeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halogeno, C1-C4-alquilo, etc.; X e Y nitrogeno, o metilo; Z es nitrogeno oCR10. Por lo menos uno de los eslabones del ciclo X, Y o Z es nitrogeno; R3 es hidrogeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halogeno,C1-C4-alquilo, etc.; R4 y R5 (que pueden ser iguales o distintos)son: fenilo o naftilo que pueden ser sustituidos por uno o más de los siguientes residuos:halogeno, nitro, ciano, hidroxi, mercapto, C1-C4-alquilo, etc.; R6 es C3-C8- cicloalquilo, en donde estos residuos pueden sersustituidos una o más vecespor: halogeno, hidroxi, mercapto, carboxi, nitro, ciano, C1-C4-alcoxi, C1-C4-alquilo, etc.; W es azufre u oxígeno; Q es un distanciador que en sulargo corresponda a una cadena C2-C4. La funcion de Q es producir enlos compuestos de la formula (I) una distancia definida entre los grupos R6 y W.También son objeto aquellos compuestos de los que se liberan los compuestos de la formula (I) (las denominadas prodrogas). Se prefieren aquellas prodrogasen las que la liberacion sucede bajo tales condiciones, como las que prevalecen en determinados compartimientos corporales, por ejemplo, el estomago, elintestino, la circulacion sanguínea, el hígado. Los compuestos y también los productos intermedios para su fabricacion, como por ejemplo (II), (III) y (IV)pueden poseer uno o más átomos de carbono sustituidos asimétricamente. Estos compuestos pueden presentarse como enantiomeros puros o diastereomeros puroso como combinacion de ellos. Se prefiere la aplicacion de un compuesto de enantiomeros puros como sustancia activa. Tambiém se describe la utilizacion
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19636046A DE19636046A1 (de) | 1996-09-05 | 1996-09-05 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009543A1 true AR009543A1 (es) | 2000-04-26 |
Family
ID=7804712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104059A AR009543A1 (es) | 1996-09-05 | 1997-09-05 | Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6670367B1 (es) |
| EP (1) | EP0929529A2 (es) |
| JP (1) | JP2000517329A (es) |
| KR (1) | KR20000068446A (es) |
| CN (1) | CN1236362A (es) |
| AR (1) | AR009543A1 (es) |
| AU (1) | AU736414B2 (es) |
| BG (1) | BG103258A (es) |
| BR (1) | BR9711693A (es) |
| CA (1) | CA2265504A1 (es) |
| CO (1) | CO4900070A1 (es) |
| DE (1) | DE19636046A1 (es) |
| HU (1) | HUP0000664A3 (es) |
| ID (1) | ID19417A (es) |
| IL (1) | IL128743A0 (es) |
| NO (1) | NO312674B1 (es) |
| NZ (1) | NZ334548A (es) |
| PL (1) | PL331998A1 (es) |
| SK (1) | SK25999A3 (es) |
| TR (1) | TR199900486T2 (es) |
| WO (1) | WO1998009953A2 (es) |
| ZA (1) | ZA977946B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
| JP2001514254A (ja) * | 1997-09-04 | 2001-09-11 | ビーエーエスエフ アクチェンゲゼルシャフト | 新規カルボン酸誘導体、その製造及び混合ｅｔａ／ｅｔｂエンドセリン受容体拮抗薬としてのその使用 |
| CZ299741B6 (cs) | 1997-09-26 | 2008-11-05 | Abbott Gmbh & Co. Kg | Kombinace endotelinového antagonisty a RAS inhibitoru a její použití, farmaceutický prostredek s jejím obsahem a zpusob výroby tohoto prostredku |
| DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE69830069T3 (de) * | 1997-10-17 | 2012-02-09 | Ark Therapeutics Ltd. | Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel |
| DE19809144A1 (de) * | 1998-03-04 | 1999-09-09 | Basf Ag | Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten |
| DE19836044A1 (de) * | 1998-08-10 | 2000-02-17 | Basf Ag | Neue Carbonsäurederivate, die Ketoseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| DE19933164A1 (de) * | 1999-07-20 | 2001-01-25 | Basf Ag | Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
| DE19951671A1 (de) * | 1999-10-27 | 2001-05-03 | Basf Ag | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
| DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
| US20030152956A1 (en) * | 2000-12-26 | 2003-08-14 | Noriko Ohtani | Method of examining allergic disease |
| ES2262567T3 (es) | 2001-03-20 | 2006-12-01 | Schwarz Pharma Ag | Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico. |
| DK1243263T3 (da) | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
| EA013591B1 (ru) | 2004-04-16 | 2010-06-30 | Шварц Фарма Аг | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| EP1781276B1 (en) | 2004-08-27 | 2010-06-23 | UCB Pharma GmbH | Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| MX2008011844A (es) * | 2006-03-13 | 2008-10-02 | Encysive Pharmaceuticals Inc | Formulaciones de sitaxsentano de sodio. |
| MX2008011842A (es) * | 2006-03-13 | 2008-10-02 | Encysive Pharmaceuticals Inc | Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica. |
| AR061476A1 (es) | 2006-06-15 | 2008-08-27 | Sanol Arznei Schwarz Gmbh | Composicion farmaceutica con efecto anticonvulsivo sinergico |
| US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
| CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
| CN103739557B (zh) * | 2013-12-30 | 2015-10-21 | 黄河三角洲京博化工研究院有限公司 | 一种4,6-二甲基-2-甲磺酰基嘧啶的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4313412A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4313413A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4335950A1 (de) | 1993-10-21 | 1995-04-27 | Basf Ag | Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung |
| DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
-
1996
- 1996-09-05 DE DE19636046A patent/DE19636046A1/de not_active Withdrawn
-
1997
- 1997-03-02 US US09/254,137 patent/US6670367B1/en not_active Expired - Fee Related
- 1997-09-02 IL IL12874397A patent/IL128743A0/xx unknown
- 1997-09-02 EP EP97943819A patent/EP0929529A2/de not_active Withdrawn
- 1997-09-02 JP JP10512203A patent/JP2000517329A/ja active Pending
- 1997-09-02 BR BR9711693A patent/BR9711693A/pt not_active IP Right Cessation
- 1997-09-02 AU AU45524/97A patent/AU736414B2/en not_active Ceased
- 1997-09-02 TR TR1999/00486T patent/TR199900486T2/xx unknown
- 1997-09-02 PL PL97331998A patent/PL331998A1/xx unknown
- 1997-09-02 CA CA002265504A patent/CA2265504A1/en not_active Abandoned
- 1997-09-02 WO PCT/EP1997/004688 patent/WO1998009953A2/de not_active Application Discontinuation
- 1997-09-02 CN CN97199458A patent/CN1236362A/zh active Pending
- 1997-09-02 HU HU0000664A patent/HUP0000664A3/hu unknown
- 1997-09-02 NZ NZ334548A patent/NZ334548A/xx unknown
- 1997-09-02 SK SK259-99A patent/SK25999A3/sk unknown
- 1997-09-02 KR KR1019997001815A patent/KR20000068446A/ko not_active Application Discontinuation
- 1997-09-04 ZA ZA977946A patent/ZA977946B/xx unknown
- 1997-09-04 CO CO97051479A patent/CO4900070A1/es unknown
- 1997-09-05 ID IDP973110A patent/ID19417A/id unknown
- 1997-09-05 AR ARP970104059A patent/AR009543A1/es not_active Application Discontinuation
-
1999
- 1999-03-04 NO NO19991079A patent/NO312674B1/no not_active IP Right Cessation
- 1999-03-16 BG BG103258A patent/BG103258A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000664A3 (en) | 2001-07-30 |
| TR199900486T2 (xx) | 1999-06-21 |
| US6670367B1 (en) | 2003-12-30 |
| AU736414B2 (en) | 2001-07-26 |
| IL128743A0 (en) | 2000-01-31 |
| NO312674B1 (no) | 2002-06-17 |
| CO4900070A1 (es) | 2000-03-27 |
| CA2265504A1 (en) | 1998-03-12 |
| BG103258A (en) | 2000-12-29 |
| CN1236362A (zh) | 1999-11-24 |
| NO991079L (no) | 1999-05-04 |
| KR20000068446A (ko) | 2000-11-25 |
| ZA977946B (en) | 1999-03-04 |
| AU4552497A (en) | 1998-03-26 |
| PL331998A1 (en) | 1999-08-16 |
| EP0929529A2 (de) | 1999-07-21 |
| DE19636046A1 (de) | 1998-03-12 |
| NZ334548A (en) | 2000-09-29 |
| HUP0000664A2 (hu) | 2001-04-28 |
| WO1998009953A3 (de) | 1998-10-29 |
| NO991079D0 (no) | 1999-03-04 |
| ID19417A (id) | 1998-07-09 |
| BR9711693A (pt) | 1999-08-24 |
| WO1998009953A2 (de) | 1998-03-12 |
| JP2000517329A (ja) | 2000-12-26 |
| SK25999A3 (en) | 1999-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009543A1 (es) | Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. | |
| LU88769I2 (fr) | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) | |
| PE20020532A1 (es) | Derivados de naftaleno como agonistas del receptor canabinoide | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| AR009357A1 (es) | Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa | |
| ITMI922006A1 (it) | Esteri nitrici di derivati dell'acido 2-(2, 6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| PA8539801A1 (es) | Derivados del ácido isoftálico como inhibidores de metaloproteinasas de la matriz | |
| PE20030612A1 (es) | Benzoimidazoles | |
| PE20060297A1 (es) | Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1 | |
| TR200000671T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. | |
| PE20091443A1 (es) | Derivados bis-(sulfonilamino) como inhibidores de la enzima prostaglandina e sintasa-1 microsomal | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
| TR200100410T2 (tr) | 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri. | |
| PE20070318A1 (es) | Metodo para purificar tigeciclina | |
| HUP0002122A2 (hu) | Ciklusos tio-szubsztituált acilaminosav-amid származékok | |
| PT1202957E (pt) | Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha | |
| PE20030944A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| CR10974A (es) | Inhibidores de carboxipeptidasa b plasmatica (divisional) | |
| PE20050035A1 (es) | COMPUESTOS DE FENILINDOL PARA MODULAR LA IgE E INHIBIR LA PROLIFERACION CELULAR | |
| AR041861A1 (es) | Feniliso (tio) cianatos, procesos e intermediarios para su preparacion. | |
| AR008621A1 (es) | Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto | |
| CO5160251A1 (es) | Analogos de prostaglandinas selectivos del receptor fp c16 insaturados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |